We present a 37 years’ experience in the management of biliary atresia (BA) and discuss long-term complications after Kasai portoenterostomy (KPE). A retrospective territory-wide study from 1980 to 2017 on 231 patients with open KPE from three tertiary paediatric surgical centres was performed. Outcome parameters were clearance of jaundice (COJ), native liver survival (NLS) and long-term complications. Factors affecting the operative outcomes were analyzed. The median duration of follow up was 17.5 (IQR: 13.5–22) years. Over 66% of patients became jaundice-free at 1 year after KPE. Seventy patients (30.3%) received liver transplant (LT) at a median age of 6.2 (IQR: 4.3–8.4) years. The NLS rates at 10 and 20 years were 70.7% and 61.5% respectively with no significant change over the study period. The median age at KPE was 59 (IQR: 49–67) days. KPE performed before 70 days was associated with higher odd ratios for successful drainage but the age of KPE did not have an impact on the long-term NLS. Among all native liver survivors (n = 153), the median bilirubin level was 24 (IQR: 16–36) µmol/L. Portal hypertension (PHT) and recurrent cholangitis were found in 51.6% and 27.5% of them respectively. With a vigilant follow up program, more than 60% of BA patients could remain stable with the disease and achieve long-term survival without LT. Although cholestasis, portal hypertension and recurrent cholangitis are common in long-term NLS, with a comprehensive follow management strategy, they do not always necessitate LT. Our study serves as an example for countries where deceased donor organs are scarce due to very low donation rate.

Abbreviations

BA  Biliary atresia
COJ  Clearance of jaundice
KPE  Kasai portoenterostomy
LT  Liver transplant
MELD  Model for end-stage liver disease
NLS  Native liver survival
OGV  Oesophago-gastric varices
PELD  Pediatric end-stage liver disease
PHT  Portal hypertension

Biliary atresia (BA) is a progressive fibrosclerosing disease of the biliary tract and affects all ethnicities with a noticeably higher incidence in the Asia–Pacific region. Kasai portoenterostomy (KPE) is by far the most widely accepted primary treatment with a variable outcome. Liver transplant (LT) is regarded as the salvage treatment.
when KPE fails to restore biliary drainage. KPE is also labelled as failure when patients develop complications related to recurrent cholangitis, portal hypertension (PHT) and hepatic dysfunction which could happen in 60% of BA patients. These complications are often indications for LT. Literatures from various studies have reported that early drainage rate is in the range of 50% to 60% and only less than half of the patients could remain transplant-free after KPE. In addition, it was estimated that around half of the LT will be performed before the age of 2. Although LT is a potential treatment for these complications, transplant recipients need to face the problems associated with an ultra-major operation and the life-long use of immunosuppressants. This could impair the immune system, leading to recurrent infection and most severely, haematological malignancy. Even worse, this notorious side-effect is more pronounced in children. In some countries, another major hurdle to LT is the low organ donation rate. Thus, eliminating or deferring the need of LT for as long as possible is a legitimate goal for BA treatment. The main purposes of this study were (1) to describe our territory-wide experience in managing BA and report the treatment outcomes of KPE based on 37 years’ follow up data; and (2) to present the long-term problems encountered by native liver survivors and discuss management strategies other than LT.

Methods

Study design and patients. This was a retrospective regional-based study conducted in the only three tertiary paediatric surgical centres performing KPE in Hong Kong. A list of BA patients receiving treatment between 1980 and 2017 was retrieved and their medical records were reviewed. This study has been approved by the University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (HKU/HA HKW IRB number: UW20-156) and was performed in accordance with the ethical standards in the Declaration of Helsinki. Informed consent from parents and/or legal guardians for study participation have been obtained.

The management strategies of BA in Hong Kong. In Hong Kong, the three centres broadly adopted a common approach for BA over the years. The diagnosis of BA was established by surgical exploration +/- cholangiogram and liver biopsy. KPE remained the preferred primary treatment option for BA, except when the patients presented over 100 days and/or surgical exploration revealed a grossly cirrhotic liver. In those situations, the chief surgeons decided to proceed with KPE or not and for the latter case, the patients would be referred for LT. All KPEs were performed by an experienced paediatric surgeon who had completed fellowship training for more than 5 years and assisted KPE for at least 10 times. In this way, surgical expertise is guaranteed. To ensure an adequate training of the next generation, younger surgeons were also present during the operations. KPE was performed by conventional open approach according to the original principle with minor technical variations, except 16 laparoscopic KPEs were performed by a single surgeon in one of the centres from 2002 to 2006. The operation started with a right subcostal or upper transverse abdominal incision. The liver was either completely mobilized and everted out of the wound or remained attaching with the ligaments. The right and left portal veins were used as the reference landmarks for hilar dissection, which was followed by a 30 to 45 cm Roux-en-Y biliary reconstruction. Porto-enterostomy was anastomosed using 5/0 or 6/0 absorbable sutures.

Post-operatively, enteral feeding was resumed once the bowel function had returned. Ursodeoxycholic acid, fat-soluble vitamins and antibiotics were prescribed. Since 2004, 169 patients have received oral steroid as the adjuvant therapy after KPE with variations in the duration and dosage among the three centres. After discharge, life-long follow up was conducted by the primary surgical team for every 3 to 6 months. During each visit, complete blood count and liver function were checked. A more frequent visit would be scheduled if the liver function was abnormal or in the presence of complications necessitating a close monitoring. The clinical manifestations of PHT were actively screened. Splenomegaly was detected by clinical examination and ultrasonography. Oesophago-gastric varices (OGV) were managed by endoscopic sclerotherapy or banding. Medications for PHT were prescribed to patients with symptomatic PHT after discussion of their potency and potential side-effects. All patients admitted with fever and raised bilirubin level were promptly treated as cholangitis with at least two weeks of antibiotics after full septic work up. Radiological investigations were performed to look for liver abscesses/cysts or other structural anomalies in resistant cases. A central venous catheter would be inserted if more than 4 weeks of antibiotics was expected. Patients with BA-related complications admitted to district hospitals other than these three paediatric surgical centres were transferred back to the parent team for management. The paediatric LT programme started in 1993 and both living as well as deceased donor LT were performed. The decision of LT was jointly reviewed by the paediatric surgical and the LT teams.

Registered data and outcome measurements. The medical records were retrieved using ICD-9 coding ‘751.61: Biliary atresia’; ‘51.37: Kasai portoenterostomy’ and ‘50.59: Transplant of liver’. Demographic information, peri-operative details, clinical and laboratory data including serum bilirubin and albumin level; international normalized ratio (INR) and platelet count were extracted. In all patients, the outcome measures were COJ (total serum bilirubin level < 20 µmol/L) and native liver survival (NLS) rates after KPE. NLS was defined as survival with own liver and has not been listed for LT at the time of writing. For native liver survivors, additional analysis included the assessment of growth and liver function. The following complications were evaluated: (i) hypersplenism which was defined by a clinically palpable spleen/spleen length above age-specific value in abdominal ultrasound and platelet count < 150 × 10^9/L; (ii) OGV of any grade detected during surveillance or emergency endoscopy; and (iii) recurrent (> 1 episode) cholangitis. An episode of cholangitis was defined by the presence of fever (core body temperature > 38.5 degree Celsius) and bilirubin level > 20 µmol/L on two consecutive blood samples requiring intravenous antibiotics treatment. An episode that required more than 2 weeks of antibiotics or intervention was regarded as severe cholangitis. In this study, the exclusion criteria
for outcome analysis were (i) incomplete medical record or laboratory data; (ii) loss of follow-up data for more than 3 consecutive years; (iii) KPE performed by laparoscopic approach and iv) LT as the primary procedure.

**Statistical analysis.** Scientific analysis was performed with a standard statistical package (Windows, version 26.0; SPSS Inc., Armonk, NY, USA). Categoric variables were compared with Chi-square test. Continuous variables were reported as medians (interquartile range) and compared with Kruskal–Wallis test. NLS was estimated with Kaplan–Meier analysis. Logistic regression analysis was performed to identify factors associated with COJ at 1 year after KPE. A p-value of less than 0.05 was considered to be statistically significant.

**Human transplantation research declaration.** NO organs/tissues were procured from prisoners. Organ procurement for liver transplantation in this study was performed by the Division of Liver Transplantation, Department of Surgery, Queen Mary Hospital, The University of Hong Kong.

**Results**

**Study population.** During the study period, there were 289 BA patients identified with more female than male (F:M = 168:121). Between 1996 to 2017, the annual incidence of BA in Hong Kong ranged from 1.18 to 1.86 per 10,000 live births (Fig. 1). Fifty-eight patients were excluded from this study because of (i) incomplete medical record (n = 12); (ii) follow up visit defaulted (n = 18); (iii) laparoscopic KPE (n = 16) and (iv) LT as the primary procedure (n = 7). Furthermore, 5 patients who died of liver failure without any surgical treatment were also excluded. As a result, 231 patients with conventional open KPE as the primary surgical procedure were included (Fig. 2). The majority of them (98%) suffered from type III BA and 17 patients had syndromic association including Biliary Atresia Splenic Malformation (BASM). The median age at KPE was 59 (IQR: 49–67) days. In this study, all patients were followed up at their respective centres and the median duration of follow up was 17.5 (IQR: 13.5–22.0) years. The demographic data were summarized in Table 1.

**Post-KPE outcomes (n = 231).** Clearance of jaundice. COJ was defined as serum total bilirubin level $\leq 20 \mumol/L$. Patient who have received LT were considered as failure of COJ as none of them had a normal bilirubin level prior to LT. The COJ rates at 1 and 2 years after KPE were 66.7% and 64.5% respectively. By logistic regression analysis, performing KPE before 70 days was associated with higher odds ratios for normal bilirubin level at 1 year after KPE (Table 2).
Native liver survival. Until the last follow up, 153 patients (66.2%) were still surviving with their own liver (Table 2). Forty-three of them (28.1%) have reached adulthood (≥ 18 years). Seventy-patients (30.3%) received LT at a median age of 6.2 (IQR: 4.3—8.4) years and 8 patients (3.4%) were recorded death after KPE without transplant. The indications for LT included: liver failure and the median Paediatric End-Staged Liver Disease (PELD)/Model for End-Staged Liver Disease (MELD) score was 16.4 (IQR: 13.5 – 24.3) (n = 59); severe portal hypertension (n = 7) and recurrent cholangitis (n = 4). Four patients presented with shortness of breath and were diagnosed with hepatopulmonary syndrome before LT. Kaplan–Meier analysis estimated the 10- and 20- year NLS rate were approximately 70.7% and 61.5%, respectively (Fig. 3A). There was no significant difference in the NLS rate when we compared the age at KPE and the use of adjuvant steroid therapy before and after 2004 (Fig. 3B,C).

Table 1. Demographic data and clinical outcomes of 231 BA patients with open KPE performed in Hong Kong between 1980 and 2017. *Failure of clearance of jaundice (COJ) is defined as serum bilirubin > 20 µmol/L or transplanted.

| Patient characteristics | Number (%) or median (IQR) |
|-------------------------|---------------------------|
| Sex                     |                           |
| Male                    | 97 (42.0%)                |
| Female                  | 134 (58.0%)               |
| Associated major anomalies |                         |
| Yes                     | 17 (7.4%)                 |
| No                      | 214 (92.6%)               |
| Age at KPE (days)       |                           |
| <51 days                | 60 (25.9%)                |
| 51 to 60 days           | 63 (27.3%)                |
| 61 to 70 days           | 57 (24.7%)                |
| >70 days                | 51 (22.1%)                |
| Use of adjuvant steroid since 2004 |         |
| Yes                     | 169 (73.2%)               |
| No                      | 62 (26.8%)                |
| Duration of follow up (years) | 17.5 (13.5–22.0)        |
| Jaundice clearance*     |                           |
| 1 year after KPE        | 154 (66.7%)               |
| 2 years after KPE       | 149 (64.5%)               |

Table 2. Percentage and odds ratio from logistic regression for the relation between different clinical variables and clearance of jaundice (COJ) at 1 year after KPE (n = 154/231, 66.7%).

|                                      | Number of patients | Number and % of patients achieving COJ at 1 year after KPE | P   | Odds ratio (95% CI) | P   |
|--------------------------------------|--------------------|-----------------------------------------------------------|-----|---------------------|-----|
| Gender                               |                    |                                                           |     |                     |     |
| Male                                 | 97                 | 65 (67.0%)                                               | 0.574 | 0.81 (0.43–1.38)   | 0.483|
| Female                               | 134                | 89 (66.4%)                                               | 1   |                     |     |
| Associated major anomalies           |                    |                                                           |     |                     |     |
| Yes                                  | 17                 | 10 (58.8%)                                               | 0.819 | 1.14 (0.74–1.86)   | 0.572|
| No                                   | 214                | 144 (67.2%)                                              | 1   |                     |     |
| Age at KPE (days)                    |                    |                                                           |     |                     |     |
| <51                                  | 60                 | 41 (68.3%)                                               | 0.046 | 1.43 (0.92–1.93)   | 0.041|
| 51 to 60                             | 63                 | 42 (66.7%)                                               | 1.67 (1.45–1.85) | 0.038 |
| 61 to 70                             | 57                 | 40 (70.2%)                                               | 1.89 (1.76–1.99) | 0.032 |
| >70                                  | 51                 | 31 (60.8%)                                               | 1   |                     |     |
| COJ at 1 month after KPE             |                    |                                                           |     |                     |     |
| Yes                                  | 28                 | 20 (71.4%)                                               | 0.228 | 1.58 (0.66–1.93)   | 0.071|
| No                                   | 203                | 134 (66.0%)                                              | 1   |                     |     |
| Adjuvant steroid therapy             |                    |                                                           |     |                     |     |
| Yes                                  | 169                | 115 (68.0%)                                              | 0.132 | 1.23 (0.72–1.64)   | 0.081|
| No                                   | 62                 | 39 (62.9%)                                               | 1   |                     |     |
Figure 3. (A) The overall native liver survival of 231 BA patients after KPE from 1980 to 2017. (B) Native liver survival according to the age at KPE (n = 231, p = 0.486). (C) The effect of adjuvant steroid therapy on native liver survival after open KPE (n = 231, p = 0.186).
Clinical conditions of the native liver survivors (n = 153) (Table 3). Liver function and growth. Among 153 native liver survivors, 99 patients (64.7%) were jaundice-free at the most recent follow up and the median bilirubin level of them was 24 (IQR: 16–36) µmol/L. Concerning the synthetic liver function, 94.8% and 91.5% of patients had a normal INR and albumin level for age. The median centile of body weight and height for patient younger than 18-year old were 56 (IQR: 48–70) and 62 (IQR: 53–72) respectively. For adult patients, the median body mass index was 24.2 (IQR: 22.4–26.3). When we compared the clinical conditions between patients with and without jaundice, there were no significant differences in their growth and liver synthetic functions.

Hypersplenism. All native liver survivors underwent ultrasound scan during follow up visit. Splenomegaly was found in 79 patients (51.6%). The median platelet count was 145 × 10⁹ (IQR: 81–256 × 10⁹) /L.

Oesophageo-gastric varices (OGV). At least one upper endoscopy was performed in 53 native liver survivors. The median age for the first endoscopy to be performed was 7 (IQR: 4–11) years. Among them, 31 patients (58.4%) were found to have OGV and the youngest patient was a 3 year old boy. Twelve patients experienced at least one bleeding episode requiring emergency endoscopic intervention.

Recurrent cholangitis. Forty-two native liver survivors (27.5%) suffered from more than one episode of cholangitis until the last follow up. The episode was regarded as severe in 13 patients who required antibiotics for more than two weeks. Their median bilirubin level upon admission was 52 (IQR: 26–212) µmol/L. Three patients with dilated intra-hepatic ducts required percutaneous transhepatic biliary drainage. After the removal of the drainage catheter, the three of them continued to survive without LT. Liver abscess were identified in 5 patients. While 3 patients responded to antibiotics therapy, 2 of them required image-guided drainage of pus. All of them recovered and remained transplant-freed. The median age to experience the first episode of cholangitis was 2 (IQR: 1.3–5.5) years. Five patients had their first cholangitic episode after adulthood.

Discussion

The incidence of BA in our locality is close to other Asian countries and is slightly higher than the Caucasian population. However, we have a lower incidence of syndromic association. We observed a higher incidence between 2006 and 2015 and this could be due to the transient immigration policy that allowed eligible women from Mainland China, one of the countries with the highest incidence of BA, to deliver their babies in Hong Kong during that period. Interestingly, although our incidence is higher than Western countries, we are not regarded as high-volume centres due to the small actual case number annually. To overcome the problem of limited patient volume, all BA patients in our public health care system are treated in the three centres in this study and the KPE always involved the experienced surgeons. Hence, the results of this cohort were relatively consistent across different eras when we compared the NLS before and after the introduction of adjuvant steroid therapy in 2004. This was achieved by the adherence to the same overarching surgical principle, the same peri-operative management and regular sharing of clinical experience among the three centres. The concentration of expertise in a small number of centres has enhanced our surgical outcomes with a 66.7% COJ rate achieved at the first year after KPE. Our analysis revealed that KPE before day 70 of life was associated with a higher chance of successful drainage. In this study, we did not identify any benefit associated with adjuvant steroid therapy. However, our steroid protocol was not standardized and hence we could not make a definitive conclusion. Herein, we included open KPE only because the results of laparoscopic KPE performed for a short period in one local centre were shown to be inferior to open KPE, a finding which corroborated with other international

| Clinical condition/blood parameter | Number (%) or median value (IQR) | Total (n = 153) | Jaundice + ve (n = 54) | Jaundice - ve (n = 99) | P |
|-----------------------------------|----------------------------------|----------------|----------------------|----------------------|---|
| Growth                            |                                 |                |                      |                      |   |
| Body weight centile (< 18 years)  | 56 (48–70)                      | 54 (46–63)     | 57 (49–68)           | 0.451                |   |
| Body height centile (< 18 years)  | 62 (53–72)                      | 63 (53–69)     | 60 (53–75)           | 0.678                |   |
| BMI (≥ 18 years)                  | 24.2 (22.4–26.3)                | 23.6 (22.8–25.8) | 25.1 (23.6–26.5)     | 0.382                |   |
| Bilirubin level (µmol/L)          | 24 (16–36)                      | 29 (24–35)     | 14 (10–16)           | 0.021                |   |
| Albumin (g/L)                     | 37 (32–42)                      | 35 (31–39)     | 36 (34–40)           | 0.245                |   |
| INR                               | 1.1 (1.0–1.3)                   | 1.0 (0.9–1.1)  | 1.1 (1.0–1.2)        | 0.488                |   |
| Platelet* (× 10⁹)                 | 145 (81–256)                    | 135 (90–210)   | 152 (122–184)        | 0.503                |   |
| Hypersplenism*                    | 79 (51.6%)                      | 35 (64.8%)     | 44 (44.4%)           | 0.369                |   |
| OGV^                              | 31/53 (58.4%)                   | –             | –                    | –                    |   |
| Recurrent cholangitis*            | 42 (27.5%)                      | 18 (33.3%)     | 24 (24.2%)           | 0.213                |   |

Table 3. The latest clinical conditions of the 153 native liver survivors of BA. Jaundice is defined as total serum bilirubin level > 20 µmol/L. *Percentage calculated based on 153 native liver survivors. ^As the percentage was calculated based on the 53 patients who have received upper endoscopy, the comparison between jaundice + ve and – ve was not performed.
We believe an aggressive management approach to cholangitis is necessary to prevent it from becoming intrahepatic. Therefore, whenever a patient with a history of liver transplantation presents with an elevated bilirubin level, we labelled the episode as cholangitis only if jaundice persisted upon two blood taking. Persistent jaundice will undergo full work-up, followed by broad-spectrum antibiotics for at least 2 weeks to rule out any other cause of jaundice, without an identifiable anatomical obstruction. All patients with clinical feature of cholangitis, namely fever and deranged liver function tests, should therefore maintain a high index of suspicion in any BA survivors with fever and deranged liver function.

We believe an aggressive management approach to cholangitis is necessary to prevent it from becoming intractable that ultimately worsens the prognosis. Liver abscess and ductal dilatation, though uncommon, should be actively sought out and external drainage can be performed if necessary. Even though cholangitis occurred shortly after KPE, it can happen at any time and the first presentation can be at adulthood. Follow-up providers need to be aware of the possibility of recurrent cholangitis, especially in patients with a history of liver transplantation. Surveillance upper endoscopy should be performed in every BA patient to screen for OGV, preferably starting at 4 years after KPE. Prophylactic treatment by sclerotherapy or banding can be performed when OGV is detected. This policy should continue when the patient is transitioned to adult care. Patients should be monitored for at least 2 weeks to ensure adequate coverage. Clinically, in order to differentiate from common cold which may also lead to a mildly elevated bilirubin level, we labelled the episode as cholangitis only if jaundice persisted upon two blood taking. We believe an aggressive management approach to cholangitis is necessary to prevent it from becoming intractable that ultimately worsens the prognosis. Liver abscess and ducal dilatation, though uncommon, should be actively sought out and external drainage can be performed if necessary. Even though cholangitis occurred shortly after KPE, it can happen at any time and the first presentation can be at adulthood. Follow-up providers should therefore maintain a high index of suspicion in any BA survivors with fever and deranged liver function. Knowledge in this could expedite the treatment process. Occasionally, long term prophylactic antibiotic is necessary to prevent recurrence. Home intravenous antibiotics administration has been reported with success especially in compact city where home-hospital distance is short.

The value of KPE as the primary treatment has been challenged by the high post-Kasai LT rate (24). While it is still true that BA is the most common indication for paediatric LT, our survival analysis revealed that more than 60% of our patients could remain transplant free as far as 20 years after KPE. This survival rate is comparable to the results reported by some high-volume centres. We believe KPE should still be regarded as the primary treatment in experienced centres and LT should be regarded as a salvage treatment unless the presentation is late when KPE is bound to result failure. Nevertheless, the definition of late remains arbitrary and mostly it is a clinical judgement. From our data, the median bilirubin level among the native liver survivors was 24 µmol/L only and their growth was normal. There was no significant difference between those with and without jaundice. These findings, together with the conclusion from the previous study by Wong et al. on the quality of life among BA survivors, has indicated that most post-KPE patients with mild cholestasis may not require LT if their complications are well managed and many can indeed survive with the disease. Regarding the optimal timing of LT after KPE, in our previous study focusing on all transplant recipients, we concluded that LT should be considered only when PELD/MELD score was greater than 15. Taking into account the risk–benefit ratio, the involvement of the paediatric surgical team in the long term management of these patients also facilitates the practice of personalized medicine due to a better knowledge in the patient's history. For in-patient care, thanks to the geographical advantage in our city, patients could be easily transferred back to the parent hospital within a couple of hours for further management of disease-related complications. Under this management strategy, in addition to maximizing NLS, the timing of LT could also be prolonged to beyond 4 years, the median age for LT among BA patients previously reported by a multicentre study in the US. We understand the threshold for listing a patient for LT could be different among different centres. Herewith, our purpose was to share our experience in how to avoid LT as long as possible when there is a scarcity of organ donors. Table 4 summarized our recommended management strategies for patients living with native livers after KPE.

A major strength of our study is the relatively large sample size for a rare congenital disease as well as the availability of long-term data. However, we acknowledge there are several limitations to our study. First, 30 patients (12.9%) were excluded and their data could not be used. Second, the inconsistent policy regarding surveillance
endoscopy and adjuvant steroid therapy have affected the analysis of their true clinical implications. Third, the broad spectrum of severity in cholangitis has precluded an in-depth analysis of the associated risk factors and its impact on NLS. Lastly, due to the inherent retrospective nature of the study, some clinical information such as family history and microbiology results were not available.

In summary, the native liver survival of BA patients treated in a low- to mid-volume centre can be prolonged by the centralization of surgical care and a comprehensive follow up programme. The participation of the paediatric surgical team in the long-term management of BA patients enhances the delivery of precision care. While BA-related complications are common and clinically important, it is possible to avoid or defer LT with meticulous attention to them. Specifically, native liver survivors should be monitored closely for the development of PHT and cholangitis. OGV are common and early surveillance is therefore recommended to avoid life threatening bleeding. Post-Kasai patients with mild cholestasis and normal growth may not require LT. In places with shortage of organ donor, avoiding LT brings a remarkable benefit to the patients and the society. At patient level, children could be spared from a high risk ultra-major operation at young age and the use of immunosuppressants is delayed. To the society, the liver grafts which are valuable social resources, can be allocated to other liver failure patients and more lives will be saved.

Received: 27 January 2021; Accepted: 18 May 2021
Published online: 27 May 2021

**References**

1. Chong, P. H. Y., Zheng, S. & Tam, P. K. H. Biliary atresia: east versus west. *Semin. Pediatr. Surg*. **29**(4), 150950 (2020).
2. Tam, P. K. H. et al. Advances in paediatric gastroenterology. *Lancet* **390**(10099), 1072–1082 (2017).
3. Nio, M. Japanese biliary atresia registry. *Pediatr. Surg. Int.* **33**(12), 1319–1325 (2017).
4. Davenport, M. et al. Biliary atresia in England and Wales: results of centralization and new benchmark. *J. Pediatr. Surg.* **46**(9), 1689–1694 (2011).
5. Jimenez-Rivera, C., Jolin-Dahel, K. S., Fortinsky, K. J., Gozdyra, P. & Benchimol, E. I. International incidence and outcomes of biliary atresia. *J. Pediatr. Gastroenterol. Nutr.* **56**(4), 344–354 (2013).
6. Sundaram, S. S., Mack, C. L., Feldman, A. G. & Sokol, R. J. Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care. *Liver Transpl.* **23**(1), 96–109 (2017).
7. Miloh, T. et al. Immunosuppression in pediatric liver transplant recipients: unique aspects. *Liver Transpl.* **23**(2), 244–256 (2017).
8. Livesey, E. et al. Epidemiology of biliary atresia in England and Wales (1999–2006). *Arch. Dis. Child Fetal Neonatal Ed.* **94**(6), F451–F455 (2009).
9. Schreiber, R. A. et al. Biliary atresia: the Canadian experience. *J. Pediatr.* **151**(6), 659–665 (2007).
10. Nio, M. et al. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. *J. Pediatr. Surg.* **38**(7), 997–1000 (2003).
11. Hsiao, C. H. et al. Universal screening for biliary atresia using an infant stool color card in Taiwan. *Hepatology* **47**(4), 1233–1240 (2008).
12. Chan, K. W. et al. From laparoscopic to open Kasai portoenterostomy: the outcome after reintroduction of open Kasai portoenterostomy in infant with biliary atresia. *Pediatr. Surg. Int.* **30**(6), 605–608 (2014).
13. Wong, K. K., Chung, P. H., Chan, K. L., Fan, S. T. & Tam, P. K. Should open Kasai portoenterostomy be performed for biliary atresia in the era of laparoscopy? *Pediatr. Surg. Int.* **24**(8), 931–933 (2008).
14. Hussain, M. H., Alizai, N. & Patel, R. Outcomes of laparoscopic Kasai portoenterostomy for biliary atresia: a systematic review. *J. Pediatr. Surg.* **52**(2), 264–267 (2017).
15. Huang, S. Y., Yeh, C. M., Chen, H. C. & Chou, C. M. Reconsideration of laparoscopic Kasai operation for biliary atresia. *J. Laparoendosc. Adv. Surg. Tech. A.* **28**(2), 229–234 (2018).

### Table 4. Recommended management strategies of patients living with native livers after KPE.

| Strategy                                                                                          |
|--------------------------------------------------------------------------------------------------|
| **Liver failure**                                                                                 |
| Patients should receive life-long follow up, preferably by the primary surgical teams who are knowledge in BA-related complications |
| Liver function and growth status should be checked every 3 to 6 months                             |
| Monitor PELD/MELD score and consider referral to liver transplant if the score is over 15         |
| **Portal hypertension**                                                                           |
| The first surveillance endoscopy should be performed starting from the fourth year after KPE to look for OGV |
| Treat OGV prophylactically by endoscopic injection sclerotherapy or banding                         |
| Instead of an ‘on-demand’ basis, endoscopy should be performed regularly                          |
| In addition to physical examination, ultrasonography should be performed regularly to monitor splenomegaly |
| If available, non-invasive measurement of liver stiffness should be carried out during the follow up|
| Medical treatment such as beta-blocker can be prescribed in symptomatic PHT but the potency and potential side-effects should be discussed |
| **Cholangitis**                                    |
| Always maintain a high index of suspicion for possible cholangitis for any post-KPE patients admitted with fever and jaundice |
| Close monitoring for any clinical deterioration                                                    |
| An episode should be treated by potent antibiotics with adequate duration                          |
| In refractory cases, radiological imaging can be arranged to look for liver abscess or dilated intra-hepatic ducts that are treatable by interventional procedures |
| Consider long-term prophylactic antibiotics in patients with recurrent cholangitis                  |
Scientific Reports | (2021) 11:11207 | https://doi.org/10.1038/s41598-021-90860-w

16. Shirota, C. et al. Laparoscopic Kasai portoenterostomy is advantageous over open Kasai portoenterostomy in subsequent liver transplantation. Surg. Endosc. 34(8), 3375–3381 (2020).
17. Samyn, M. Transitional care of biliary atresia. Semin. Pediatr. Surg. 29(4), 159048 (2020).
18. Grammatikopoulos, T., McKierman, P. J. & Dhawan, A. Portal hypertension and its management in children. Arch. Dis. Child. 103(2), 186–191 (2018).
19. Kassam, A. F. et al. Natural course of pediatric portal hypertension. Hepatol. Commun. 4(9), 1346–1352 (2020).
20. Duche, M., Ducot, B., Ackermann, O., Jacquemin, E. & Bernard, O. Progression to high-risk gastroesophageal varices in children with biliary atresia with low-risk signs at first endoscopy. J. Pediatr. Gastroenterol. Nutr. 60(3), 664–668 (2015).
21. Wanyt, C., Helleputte, T., Smets, F., Sokal, E. M. & Stephenne, X. Assessment of risk of bleeding from esophageal varices during management of biliary atresia in children. J. Pediatr. Gastroenterol. Nutr. 56(5), 537–543 (2013).
22. Jain, V. et al. Prognostic markers at adolescence in patients requiring liver transplantation for biliary atresia in adulthood. J. Hepatol. 71(1), 71–77 (2019).
23. Hukkanen, M. et al. Noninvasive evaluation of liver fibrosis and portal hypertension after successful portoenterostomy for biliary atresia. Hepatol. Commun. 3(3), 382–391 (2019).
24. Ling, S. C. et al. Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research. J. Pediatr. Gastroenterol. Nutr. 52(3), 254–261 (2011).
25. Back, S. H. et al. The epidemiology and etiology of cholangitis after Kasai portoenterostomy in patients with biliary atresia. J. Pediatr. Gastroenterol. Nutr. 70(2), 171–177 (2020).
26. Chung, P. H. Y., Tam, P. K. H. & Wong, K. K. Y. Does the identity of the bacteria matter in post-Kasai cholangitis? A comparison between simple and intractable cholangitis. J. Pediatr. Surg. 53(12), 2409–2411 (2018).
27. Shin, J. H., Chang, E. Y., Chang, H. K., Kim, S. M. & Han, S. J. Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies. J. Korean Surg. Soc. 80(5), 355–361 (2011).
28. Kelay, A. & Davenport, M. Long-term outlook in biliary atresia. Semin. Pediatr. Surg. 26(5), 295–300 (2017).
29. Squires, R. H. et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 59(1), 112–131 (2014).
30. Wong, C. W. Y., Chang, P. H. Y., Tam, P. K. H. & Wong, K. K. Y. Long-term results and quality of life assessment in biliary atresia patients: a 35-year experience in a tertiary hospital. J. Pediatr. Gastroenterol. Nutr. 66(4), 570–574 (2018).
31. Chung, P. H. Y., Chok, K. S. H., Wong, K. K. Y., Tam, P. K. H. & Lo, C. M. Determining the optimal timing of liver transplant for pediatric patients after Kasai portoenterostomy based on disease severity scores. J. Pediatr. Surg. 55(9), 1892–1896 (2020).
32. Schneider, B. L. et al. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J. Pediatr. 148(4), 467–474 (2006).

Author contributions
PH.Y.C., E.K.W.C. and K.K.Y.W. conceptualized and designed the study, collected data, drafted the initial manuscript, and reviewed and revised the manuscript. F.Y., J.W.C.M. and J.W.S.H. designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript. A.C.Y.C., M.W.Y.L., K.H.L., P.K.H.T. coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding
No funding was secured for this study.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence
Requests for materials should be addressed to P.K.H.T. or K.K.Y.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021